STAAR Surgical EBITDA 2012-2026 | STAA
STAAR Surgical ebitda from 2012 to 2026. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
|
STAAR Surgical Annual EBITDA (Millions of US $) |
|
|---|---|
| 2025 | $-83 |
| 2024 | $-7 |
| 2023 | $31 |
| 2022 | $47 |
| 2021 | $37 |
| 2020 | $10 |
| 2019 | $16 |
| 2018 | $9 |
| 2017 | $0 |
| 2016 | $-10 |
| 2015 | $-3 |
| 2014 | $-6 |
| 2013 | $3 |
| 2012 | $1 |
| 2011 | $5 |
|
STAAR Surgical Quarterly EBITDA (Millions of US $) |
|
|---|---|
| 2026-06-30 | $13 |
| 2026-03-31 | $10 |
| 2025-12-31 | $-21 |
| 2025-09-30 | $20 |
| 2025-06-30 | $-28 |
| 2025-03-31 | $-55 |
| 2024-12-31 | $-26 |
| 2024-09-30 | $7 |
| 2024-06-30 | $13 |
| 2024-03-31 | $-1 |
| 2023-12-31 | $11 |
| 2023-09-30 | $7 |
| 2023-06-30 | $9 |
| 2023-03-31 | $3 |
| 2022-12-31 | $1 |
| 2022-09-30 | $14 |
| 2022-06-30 | $18 |
| 2022-03-31 | $13 |
| 2021-12-31 | $8 |
| 2021-09-30 | $9 |
| 2021-06-30 | $12 |
| 2021-03-31 | $8 |
| 2020-12-31 | $5 |
| 2020-09-30 | $6 |
| 2020-06-30 | $0 |
| 2020-03-31 | $0 |
| 2019-12-31 | $3 |
| 2019-09-30 | $4 |
| 2019-06-30 | $5 |
| 2019-03-31 | $3 |
| 2018-12-31 | $2 |
| 2018-09-30 | $2 |
| 2018-06-30 | $4 |
| 2018-03-31 | $1 |
| 2017-12-31 | $0 |
| 2017-09-30 | $2 |
| 2017-06-30 | $0 |
| 2017-03-31 | $-1 |
| 2016-12-31 | $2 |
| 2016-09-30 | $-1 |
| 2016-06-30 | $-1 |
| 2016-03-31 | $-9 |
| 2015-12-31 | $1 |
| 2015-09-30 | $-1 |
| 2015-06-30 | $-1 |
| 2015-03-31 | $-1 |
| 2014-12-31 | $-3 |
| 2014-09-30 | $-1 |
| 2014-06-30 | $-1 |
| 2014-03-31 | $-1 |
| 2013-12-31 | $-1 |
| 2013-09-30 | $1 |
| 2013-06-30 | $1 |
| 2013-03-31 | $2 |
| 2012-12-31 | $-1 |
| 2012-09-30 | $0 |
| 2012-06-30 | $0 |
| 2012-03-31 | $1 |
| 2011-12-31 | $1 |
| 2011-09-30 | $1 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical & Dental Supplies | $1.125B | $0.239B |
| Staar Surgical Company has evolved to become a developer, manufacturer and global distributor of products used by ophthalmologists and other eye care professionals to improve or correct vision in patients suffering from refractive conditions, cataracts and glaucoma. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| McKesson (MCK) | United States | $104.880B | 22.04 |
| Cardinal Health (CAH) | United States | $54.109B | 20.66 |
| Becton Dickinson (BDX) | United States | $51.228B | 14.30 |
| West Pharmaceutical Services (WST) | United States | $25.687B | 42.94 |
| Straumann Holding AG (SAUHY) | Switzerland | $18.592B | 0.00 |
| Align Technology (ALGN) | United States | $10.528B | 16.28 |
| Cooper (COO) | United States | $10.130B | 11.56 |
| Henry Schein (HSIC) | United States | $9.754B | 16.48 |
| Merit Medical Systems (MMSI) | United States | $5.146B | 23.48 |
| DENTSPLY SIRONA (XRAY) | United States | $1.960B | 6.87 |
| CONMED (CNMD) | United States | $1.406B | 9.82 |
| Pro-Dex (PDEX) | United States | $0.214B | 19.97 |
| Lifevantage (LFVN) | United States | $0.077B | 11.04 |